Genmab to Present at the Jefferies 2014 Global Healthcare Conference
May 27, 2014 03:15 ET
|
Genmab A/S
Media Release
Copenhagen, Denmark; May 27, 2014 – Genmab A/S (OMX: GEN) announced today its CEO, Jan van de Winkel, Ph.D., will present a company update at the Jefferies 2014 Global Healthcare...
GSK og Genmab modtager positiv erklæring fra CHMP for Arzerra™ i kombination med chlorambucil eller bendamustin til førstelinjebehandling af patienter med kronisk lymfatisk leukæmi (CLL), som ikke er egnede til fludarabin-baseret behandling
May 23, 2014 08:57 ET
|
Genmab A/S
Selskabsmeddelelse
CHMP anbefaler at udstede markedsføringstilladelse for Arzerra i kombination med chlorambucil eller bendamustin til behandling af patienter med CLL, som ikke tidligere har...
GSK and Genmab Receive CHMP Positive Opinion for Arzerra™ in Combination with Chlorambucil or Bendamustine as a First-line Treatment for Patients with Chronic Lymphocytic Leukemia (CLL) Who Are Not Eligible for Fludarabine-based Therapy
May 23, 2014 08:57 ET
|
Genmab A/S
Company Announcement
CHMP recommends marketing authorization for Arzerra in combination with chlorambucil or bendamustine for patients with CLL who have not received prior therapy and are not...
Flere abstracts om daratumumab til præsentation på EHA
May 22, 2014 03:58 ET
|
Genmab A/S
Pressemeddelelse
Fire abstracts om daratumumab og to om ofatumumab præsenteres på EHA
Abstracts kan ses online på EHA's hjemmeside.
København, Danmark; 22. maj 2014 – Genmab A/S (OMX:...
Multiple Daratumumab Abstracts to be Presented at EHA
May 22, 2014 03:58 ET
|
Genmab A/S
Media Release
Four daratumumab and two ofatumumab abstracts to be presented at EHA
Abstracts available online at EHA website
Copenhagen, Denmark; May 22, 2014 – Genmab A/S (OMX: GEN)...
GSK og Genmab offentliggør top-line resultater fra pivotalt head-to-head studie med ofatumumab i kombination med kemoterapi over for rituximab i kombination med kemoterapi til behandling af recidiverende eller refraktært diffust storcellet
May 19, 2014 14:02 ET
|
Genmab A/S
Selskabsmeddelelse
Ingen statistisk signifikant forskel i progressionsfri overlevelse i behandlingsgruppen ofatumumab plus kemoterapi i forhold til rituximab plus kemoterapi
Detaljerede...
GSK and Genmab Announce Topline Results from a Pivotal Head to Head Study of Ofatumumab in Combination With Chemotherapy vs Rituximab in Combination with Chemotherapy for the Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma
May 19, 2014 14:02 ET
|
Genmab A/S
Company Announcement
No statistically significant difference in progression free survival in ofatumumab plus chemotherapy treatment arm compared to rituximab plus chemotherapy
Detailed data...
Selskabsvedtægter for Genmab A/S
May 15, 2014 11:14 ET
|
Genmab A/S
Selskabsvedtægter for Genmab A/S dateret den 14. maj 2014 er blevet offentliggjort. Selskabsvedtægterne er tilgængelige på Genmabs hjemmeside:...
Articles of Association for Genmab A/S
May 15, 2014 11:14 ET
|
Genmab A/S
Genmab A/S has published its Articles of Association dated May 14, 2014. The Articles of Association can be found on Genmab’s website: http://ir.genmab.com/releases.cfm
Contact:
Rachel Curtis...
Report Pursuant to Section 28a of the Danish Securities Trading Act
May 15, 2014 11:08 ET
|
Genmab A/S
Company Announcement
Copenhagen, Denmark; May 15, 2014 — Pursuant to Section 28a of the Danish Securities Trading Act, Genmab A/S (OMX: GEN) hereby, on behalf of managerial employees, makes public...